Dec 30, 2024
In this episode, host Shikha Jain, MD, speaks
with Opyl co-founder Damon Rasheed about using
machine learning to better predict clinical trial outcomes,
handling ethical concerns surrounding AI in health care and
more.
• Welcome to another exciting episode of Oncology
Overdrive 0:14
• About Rasheed 0:20
• The interview 0:58
• How did you end up in the AI-powered medicine and
clinical trials? 1:48
• What is Opyl, and what is TrialKey?
3:54
• Is TrialKey predominantly based in Australia or is
it available outside of Australia as well?
5:34
• Can you explain how machine learning works in order
to create these outcomes? 6:11
• How do you see people utilizing this tool in the
future based on what you have already seen?
8:30
• How have others received this? What is the feedback
you have gotten surrounding what people are excited and concerned
about with this technology?
10:50
• Does this type of product take into account the
issue of diversity in clinical trials?
13:41
• What’s next for expanding Opyl and TrialKey?
14:27
• What keeps you excited and motivated to continue
working in this space? 15:28
• If someone could only listen to the last few minutes
of this episode, what would you want listeners to take away?
19:35
• How to contact Rasheed
20:16
• Thanks for listening
20:54
Damon Rasheed is a serial entrepreneur recognized
for his groundbreaking ventures and deep expertise in machine
learning and big data.
We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rasheed can be reached at opyl.ai or trialkey.ai.
Disclosures: Jain reports no relevant financial disclosures. Rasheed reports TrialKey is powered by Opyl Limited, which is a publicly listed company operating on the ASX.